Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 1 |
2011 | 1 |
2012 | 2 |
2013 | 2 |
2014 | 1 |
2015 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Intensity of renal support in critically ill patients with acute kidney injury.
N Engl J Med. 2008 Jul 3;359(1):7-20. doi: 10.1056/NEJMoa0802639. Epub 2008 May 20.
N Engl J Med. 2008.
PMID: 18492867
Free PMC article.
Clinical Trial.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.
Coles AJ, et al. Among authors: oyuela p.
Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.
Lancet. 2012.
PMID: 23122650
Clinical Trial.
Item in Clipboard
A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH.
Cuker A, et al. Among authors: oyuela p.
Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29.
Blood. 2011.
PMID: 21960587
Free article.
Clinical Trial.
Item in Clipboard
Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program.
Caon C, Namey M, Meyer C, Mayer L, Oyuela P, Margolin DH, Rizzo M.
Caon C, et al. Among authors: oyuela p.
Int J MS Care. 2015 Jul-Aug;17(4):191-8. doi: 10.7224/1537-2073.2014-030.
Int J MS Care. 2015.
PMID: 26300705
Free PMC article.
Item in Clipboard
Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis.
Meyer D, Coles A, Oyuela P, Purvis A, Margolin DH.
Meyer D, et al. Among authors: oyuela p.
Mult Scler Relat Disord. 2013 Jan;2(1):60-3. doi: 10.1016/j.msard.2012.07.002. Epub 2012 Sep 25.
Mult Scler Relat Disord. 2013.
PMID: 25877456
Item in Clipboard
Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J.
Daniels GH, et al. Among authors: oyuela p.
J Clin Endocrinol Metab. 2014 Jan;99(1):80-9. doi: 10.1210/jc.2013-2201. Epub 2013 Dec 20.
J Clin Endocrinol Metab. 2014.
PMID: 24170099
Clinical Trial.
Item in Clipboard
Cite
Cite